Skip to main content
GRAFT POLYMER (UK) PLC logo

GRAFT POLYMER (UK) PLC — Investor Relations & Filings

Ticker · GPL ISIN · GB00BMD1Z199 LEI · 2138005PH7OJRCRPUD88 IL Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2025-08-28 Regulatory Filings
Country GB United Kingdom
Listing IL GPL

About GRAFT POLYMER (UK) PLC

https://graftpolymer.com/

GRAFT POLYMER (UK) PLC is a technology company specializing in polymer modification and the development of drug delivery systems. The company's core expertise lies in creating proprietary polymer modifiers that enable the combination of otherwise incompatible materials. This process results in cost-effective polymer alloys with enhanced mechanical characteristics, chemical resistance, and fire-retardant properties. Leveraging extensive research and development, the company provides bespoke, 'turn-key' solutions and customized products. Through its GraftBio division, the company also develops bio/pharma applications, including biological supplements and advanced drug delivery systems, supported by a strong intellectual property portfolio.

Recent filings

Filing Released Lang Actions
Solvonis secures exclusive CNS collaboration
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement (RNS) from Solvonis Therapeutics plc. It covers two primary topics: the appointment of a Chief Scientific Officer to a new role and the establishment of a Scientific Advisory Committee (governance/management update), and an 'Issue of Equity' to settle liabilities (share issuance). Since the document details a capital change (issue of new shares) and is a regulatory announcement, it fits the 'Share Issue/Capital Change' (SHA) category as it describes the specific issuance of 141,875,231 new ordinary shares.
2025-08-28 English
Media Coverage: Small Cap Idea profile
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the RNS (Regulatory News Service) 'Reach' platform. It serves to notify the public about media coverage of the company in an external publication (ThisIsMoney.co.uk). It does not constitute a formal financial report, proxy, or regulatory filing required by law, but rather a general corporate announcement regarding media presence. As it does not fit into specific categories like 10-K, ER, or M&A, it is classified as a general regulatory announcement.
2025-08-13 English
SVN-SDN-14 PTSD - Positive pre-clinical results
Regulatory Filings Classification · 1% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces positive pre-clinical results for a specific drug development programme (SVN-SDN-14). Since it is a general corporate announcement regarding business operations and R&D progress that does not fit into specific categories like financial reports, dividends, or management changes, it is classified as a Regulatory Filing (RNS).
2025-08-12 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a standard regulatory announcement regarding 'Total Voting Rights'. It provides the total number of issued shares and voting rights, which is a mandatory disclosure for companies listed on the London Stock Exchange (LSE) to allow shareholders to calculate their notification thresholds. Since this does not fit into specific categories like 'Major Shareholding Notification' (which is for the shareholder) or 'Share Issue' (which is for the act of issuance), and it is a standard regulatory disclosure provided via RNS, it falls under the 'Regulatory Filings' category.
2025-07-31 English
Translational Bridging Studies
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '22 July 2025'. It contains a headline announcing a corporate development ('SVN‑002: Translational bridging studies initiated...') and provides details about clinical trials, regulatory strategy (FDA 505(b)(2) pathway), and partnership with a service provider (WuXi AppTec). The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since the content is a specific operational update (clinical study initiation) and not a formal financial report (like 10-K or IR) or a specific announcement like a dividend (DIV) or director dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS.
2025-07-22 English
Exercise of warrants
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number : 6918R' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a specific corporate action: the exercise of warrants resulting in the issuance of new shares and a corresponding capital increase (£20,000 raised). This type of announcement, which is a formal notification to the market regarding share capital changes, fits best under 'Share Issue/Capital Change' (SHA). Although it is distributed via RNS, the core subject matter is a capital structure event, making SHA more specific than the general 'RNS' fallback. The document length (4291 chars) is substantial enough to be the primary announcement, not just a brief notice of publication.
2025-07-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.